Aspire Biopharma shares surge 10.89% premarket on positive Phase II trial data, $38M funding, and CRO partnership.

Aspire Biopharma surged 10.89% in premarket trading following the release of positive Phase II trial data for its oncology candidate ASB-301, which demonstrated improved progression-free survival and favorable safety profiles. The news coincided with a $38 million venture capital infusion and a strategic partnership with a European CRO to accelerate Phase III trials in Q1 2026. Analysts attributed the rally to renewed investor confidence in the compound’s regulatory potential and the firm’s ability to streamline late-stage development. The premarket momentum reflected optimism around the therapeutic pipeline’s commercial viability and reduced risk of trial delays, with historical patterns suggesting peak returns during FDA review periods.